- The US FDA has approved an additional indication for Regeneron Pharmaceuticals' ( NASDAQ: REGN ) Libtayo , this time as a first-line treatment in advanced non-small cell lung cancer (NSCLC) in combination with platinum-based chemotherapy.
- The indication is for patients with no EGFR, ALK or ROS1 aberrations and have metastatic or locally advanced tumors that are not candidates for surgical resection or definitive chemoradiation
- Regeneron ( REGN ) noted that the combination can be used in patients no matter their PD-L1 expression.
- Libtayo (cemiplimab) was already approved in 1L advanced NSCLC as a monotherapy in patients with high PD-L1 expression.
- Check out why Seeking Alpha contributor Edmund Ingham rates Regeneron ( REGN ) a hold.
For further details see:
Regeneron's Libtayo approved as first-line advanced NSCLC treatment with chemotherapy